Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Maximal-Cytoreductive Therapies for Patients With de Novo Metastatic Hormone-sensitive Prostate Cancer Who Achieve Oligopersistent Metastases During Systemic Treatment With Apalutamide Plus ADT (CHAMPION Study)

NCT05717582 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05717582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Maximal-Cytoreductive Therapies for Patients With de Novo Metastatic Hormone-sensitive Prostate Cancer Who Achieve Oligopersistent Metastases During Systemic Treatment With Apalutamide Plus ADT (CHAMPION Study)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2023
Completion date
December 31, 2026
Enrollment
47 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castration-sensitive prostate cancer, metastatic prostate cancer